Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:EXDI NASDAQ:GLSI NASDAQ:MOLN NASDAQ:TIL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEXDIExactus$0.00$0.04▼$0.27$38.94M4.2183,144 shs257,300 shsGLSIGreenwich LifeSciences$11.23-1.7%$11.46$8.06▼$15.50$153.07M1.6654,901 shs58,517 shsMOLNMolecular Partners$3.68-2.0%$3.70$3.36▼$7.60$148.44M1.15,024 shs2,286 shsTILInstil Bio$24.10+1.3%$26.84$10.80▼$92.00$162.68M2.16136,372 shs207,470 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEXDIExactus0.00%0.00%0.00%0.00%0.00%GLSIGreenwich LifeSciences0.00%+2.74%-7.72%+22.07%-24.78%MOLNMolecular Partners0.00%+2.68%+3.99%-4.42%-29.58%TILInstil Bio0.00%-23.49%-13.43%-26.90%-71.49%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEXDIExactus$0.00$0.04▼$0.27$38.94M4.2183,144 shs257,300 shsGLSIGreenwich LifeSciences$11.23-1.7%$11.46$8.06▼$15.50$153.07M1.6654,901 shs58,517 shsMOLNMolecular Partners$3.68-2.0%$3.70$3.36▼$7.60$148.44M1.15,024 shs2,286 shsTILInstil Bio$24.10+1.3%$26.84$10.80▼$92.00$162.68M2.16136,372 shs207,470 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEXDIExactus0.00%0.00%0.00%0.00%0.00%GLSIGreenwich LifeSciences0.00%+2.74%-7.72%+22.07%-24.78%MOLNMolecular Partners0.00%+2.68%+3.99%-4.42%-29.58%TILInstil Bio0.00%-23.49%-13.43%-26.90%-71.49%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEXDIExactus 0.00N/AN/AN/AGLSIGreenwich LifeSciences 3.00Buy$42.00274.00% UpsideMOLNMolecular Partners 3.00Buy$8.00117.63% UpsideTILInstil Bio 3.00Buy$88.50267.22% UpsideCurrent Analyst Ratings BreakdownLatest EXDI, MOLN, GLSI, and TIL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/11/2025TILInstil BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$125.00 ➝ $125.009/3/2025MOLNMolecular PartnersJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$4.50 ➝ $4.008/27/2025TILInstil BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$125.00 ➝ $125.008/20/2025GLSIGreenwich LifeSciencesNoble FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$45.008/15/2025TILInstil BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$125.00 ➝ $125.00(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEXDIExactus$2.07M0.00N/AN/A($0.09) per share0.00GLSIGreenwich LifeSciencesN/AN/AN/AN/A$0.19 per shareN/AMOLNMolecular Partners$5.65M26.27N/AN/A$3.99 per share0.92TILInstil BioN/AN/AN/AN/A$25.96 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEXDIExactus-$9.46MN/AN/AN/AN/AN/A-3,272.69%-185.29%N/AGLSIGreenwich LifeSciences-$15.79M-$1.36N/AN/AN/AN/A-700.90%-455.64%11/13/2025 (Estimated)MOLNMolecular Partners-$61.39M-$2.08N/AN/AN/AN/A-50.66%-45.13%10/30/2025 (Estimated)TILInstil Bio-$74.14M-$12.92N/AN/AN/AN/A-54.32%-33.65%11/12/2025 (Estimated)Latest EXDI, MOLN, GLSI, and TIL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/25/2025H1 2025MOLNMolecular Partners-$0.53-$0.67-$0.14-$0.67N/AN/A8/14/2025Q2 2025GLSIGreenwich LifeSciences-$0.24-$0.30-$0.06-$0.30N/AN/A8/13/2025Q2 2025TILInstil Bio-$1.72-$3.24-$1.52-$3.24N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEXDIExactusN/AN/AN/AN/AN/AGLSIGreenwich LifeSciencesN/AN/AN/AN/AN/AMOLNMolecular PartnersN/AN/AN/AN/AN/ATILInstil BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEXDIExactusN/A1.320.82GLSIGreenwich LifeSciencesN/A1.851.85MOLNMolecular PartnersN/A9.359.35TILInstil Bio0.6414.9714.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEXDIExactus0.12%GLSIGreenwich LifeSciences4.16%MOLNMolecular Partners26.55%TILInstil Bio60.56%Insider OwnershipCompanyInsider OwnershipEXDIExactus65.00%GLSIGreenwich LifeSciences51.67%MOLNMolecular Partners5.93%TILInstil Bio46.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEXDIExactus30599.01 million209.65 millionNot OptionableGLSIGreenwich LifeSciences313.63 million6.59 millionNot OptionableMOLNMolecular Partners18040.38 million37.98 millionNot OptionableTILInstil Bio4106.75 million3.61 millionNo DataEXDI, MOLN, GLSI, and TIL HeadlinesRecent News About These CompaniesInstil Bio announces ImmuneOnco presentation of ‘2510 monotherapy dataSeptember 10, 2025 | msn.comInstil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)September 10, 2025 | markets.businessinsider.comInstil Bio and ImmuneOnco Present Promising Phase 1 Data on ‘2510 in Previously Treated Squamous NSCLC PatientsSeptember 10, 2025 | quiverquant.comQInstil Bio Announces ImmuneOnco's Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)September 10, 2025 | globenewswire.comInstil Bio, Inc. (NASDAQ:TIL) is definitely on the radar of institutional investors who own 36% of the companyAugust 16, 2025 | finance.yahoo.comInstil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 13, 2025 | finanznachrichten.deInstil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 13, 2025 | globenewswire.comInstil Bio Reports Promising Phase 2 Study ResultsAugust 11, 2025 | theglobeandmail.comInstil Bio stock rises after positive data for cancer therapy in ChinaJuly 31, 2025 | za.investing.comInstil's licensed PD-L1xVEGF bispecific shows promise in China, instilling hope for upcoming US testJuly 31, 2025 | fiercebiotech.comFImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in ChinaJuly 31, 2025 | globenewswire.comUS FDA clears Instil Bio’s IND application for AXN-2510, a PD-L1xVEGF bispecific antibody, for a phase 1 trial in relapsed/refractory solid tumoursJuly 4, 2025 | pharmabiz.comPInstil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed ...July 3, 2025 | manilatimes.netMInstil Bio Announces FDA Clearance for IND of AXN-2510, Phase 1 Trial Expected by End of 2025 - NasdaqJuly 3, 2025 | nasdaq.comInstil Bio Shares Climb After FDA Clears Tumor Treatment ApplicationJuly 2, 2025 | marketwatch.comInstil Bio stock jumps after FDA clearance of IND applicationJuly 2, 2025 | in.investing.comInstil Bio Shares Surge on FDA Clearance for Investigational Cancer TherapyJuly 2, 2025 | msn.comInstil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid TumorsJuly 2, 2025 | globenewswire.comInstil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should KnowJune 20, 2025 | zacks.comWall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a BetJune 16, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEXDI, MOLN, GLSI, and TIL Company DescriptionsExactus OTCMKTS:EXDIExactus, Inc., is a farmer and manufacturer of hemp-derived phytocannabinoid products. The company sells its CBD products through its Green Goddess brand and third-party resellers. Exactus is engaged in producing industrial hemp from farms in Oregon and plans to extract and manufacture directly through cGMP facilities. Industrial hemp is a type of cannabis, defined by the federal government as having THC (tetrahydrocannabinol) content of 0.3 percent or less. THC is the psychoactive compound found in cannabis.Greenwich LifeSciences NASDAQ:GLSI$11.23 -0.19 (-1.66%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$11.49 +0.26 (+2.35%) As of 09/12/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.Molecular Partners NASDAQ:MOLN$3.68 -0.07 (-1.97%) Closing price 09/12/2025 03:56 PM EasternExtended Trading$3.72 +0.04 (+1.20%) As of 09/12/2025 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.Instil Bio NASDAQ:TIL$24.10 +0.30 (+1.26%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$24.70 +0.59 (+2.47%) As of 04:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
